Amgen

Amgen’s Imdelltra combo cuts lung cancer death risk 58%

Adding Amgen's Imdelltra (tarlatamab) to AstraZeneca's Imfinzi (durvalumab) cut the risk of death by 58% compared with Imfinzi alone in patients with extensive-stage small cell lung cancer, according to Phase 3 data presented on Saturday, October 24, at a major…

Imfinzi-Imdelltra combo shows major survival gain in small cell lung cancer

AstraZeneca and Amgen on Tuesday announced that a combination of Imfinzi (durvalumab) and Imdelltra (tarlatamab) delivered a statistically significant improvement in overall survival compared to Imfinzi alone as first-line maintenance therapy for extensive-stage small cell lung cancer, a disease in…